Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

High marks for modified-release oral PDE4 inhibitor in moderate-to-severe psoriasis
05 Apr 2023
bởiJairia Dela Cruz
The modified-release formulation of novel oral phosphodiesterase-4 (PDE4) inhibitor orismilast shows therapeutic potential in adults with moderate-to-severe psoriasis, with high rates of clinical response as compared with placebo, according to data from the phase IIb IASOS trial presented at AAD 2023.
05 Apr 2023

Oral JAK inhibitor makes headway in alopecia areata
05 Apr 2023
bởiElvira Manzano
Patients with severe alopecia areata (patchy baldness) had a dramatic hair regrowth, without serious adverse events, when treated with an investigational Janus kinase (JAK) inhibitor in the phase III THRIVE-AA2 study presented at AAD 2023.
05 Apr 2023







